Drug Trial Radar · NCT01425008
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Aug 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
149
Actual
Start
Sep 15, 2011
Primary completion
Apr 11, 2017
Study completion Oct 16, 2018
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Aug 29, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.
Conditions
- Melanoma
- Metastatic Melanoma
- Solid Tumor
- Neoplasm
Interventions
MLN2480Drug
Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and DeathsTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
- Dose Escalation Phase: Number of Participants With Dose-limiting Adverse Events (AEs)Time frame: Cycle 1 (Cycle length= 22 days [Q2D] and 28 days [QW])
- Number of Participants With TEAEs Related to Physical Examination FindingsTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
- Clinically Significant Change From Baseline in Body Weight at End of Study Visit (EOSV)Time frame: Baseline up to EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
- Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) FindingsTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
- Eastern Cooperative Oncology Group (ECOG) Performance ScoreTime frame: at EOSV (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle length =22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle length =28 days] in Expansion Phase)
- Number of Participants With TEAEs Categorized Into Investigations Related to Laboratory Test of Chemistry, Hematology or UrinalysisTime frame: Baseline up to 30 days after last dose, or start of subsequent therapy, whichever occurred first (up to Cycle 38 Days 52 [Q2D] and 58 [QW] [Cycle=22 days (Q2D) and 28 days (QW)] in Escalation Phase; Cycle 49 Day 58 [Cycle=28 days] in Expansion Phase)
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
San Francisco, California
Site not named
Denver, Colorado
Site not named
Augusta, Georgia
Site not named
Indianapolis, Indiana
Site not named
New York, New York
Site not named
Easton, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
San Antonio, Texas
Site not named
Lakewood, Washington
Site not named
Bristol, Avon, United Kingdom
Site not named
Cambridge, Cambridgeshire, United Kingdom
Site not named
Chelmsford, Essex, United Kingdom
Site not named
London, Greater London, United Kingdom
Site not named
Manchester, Greater Manchester, United Kingdom
Site not named
Oxford, Oxfordshire, United Kingdom
Site not named
Newcastle upon Tyne, Tyne & Wear, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.